New pill shows promise against lung cancer in early japanese trial
NCT ID NCT03807778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take the drug daily for up to a year or longer if their cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mobocertinib (an oral drug that targets EGFR and HER2 proteins in cancer cells)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with non-small cell lung cancer who have specific genetic mutations.
What could go wrong
This is an early-phase trial with only 53 participants, so results may not apply to all patients. Side effects are still being evaluated, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
-
Cancer Institute Hospital
Koto-ku, Tokyo, Japan
-
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
-
Hiroshima University Hospital
Hiroshima, Japan
-
Hokkaido Cancer Center
Sapporo, Hokkaido, Japan
-
Hyogo Cancer Cente
Akashi, Hyōgo, Japan
-
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
-
Kansai Medical University Hospital
Hirakata, Osaka, Japan
-
Kindai University Hospital
Sayama, Osaka, Japan
-
Kurume University Hospital
Kurume, Fukuoka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Kyushu University Hospital
Fukuoka, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
-
National Hospital Organization Kinki-Chuo Chest Medical Center
Sakai, Osaka, Japan
-
Niigata Cancer Center Hospital
Niigata, Japan
-
Okayama University Hospital
Kita-ku, Okayama-ken, Japan
-
Osaka International Cancer Institute
Osaka, Japan
-
Saitama Cancer Center
Shinden, Saitama, Japan
-
Sendai Kousei Hospital
Sendai, Miyagi, Japan
-
Tokushima University Hospital
Tokushima, Japan
-
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Bunkyo-ku, Tokyo, Japan
-
Wakayama Medical University Hospital
Wakayama, Japan
-
Yamaguchi Ube Medical Center
Ube, Yamaguchi, Japan